Glasdegib Film-Coated Tablets are an innovative Hedgehog signaling pathway inhibitor, first approved in the United States in 2018. As a targeted therapy drug, it provides a new treatment option for patients with specific acute myeloid leukemia (AML).
How Effective is Glasdegib Film-Coated Tablets in Treatment?
Core Therapeutic Effects
Glasdegib is a small-molecule inhibitor of Smoothened (SMO), which exerts its effect by blocking the Hedgehog signaling pathway.
Preclinical studies have shown that when Glasdegib is used in combination with low-dose cytarabine, it can more effectively inhibit the growth of AML tumors and reduce the proportion of CD45+/CD33+ blasts in the bone marrow.
Clinical Efficacy Performance
In the key clinical trial BRIGHT AML 1003, the combination of Glasdegib and low-dose cytarabine in the treatment of newly diagnosed AML patients showed significant survival benefits.
Compared with the use of low-dose cytarabine alone, the combination therapy regimen prolonged the median overall survival of patients.
Administration of Glasdegib Film-Coated Tablets in Special Populations
Patients with Hepatic Impairment
No dose adjustment is required for patients with mild hepatic impairment, but the effectiveness of Glasdegib in patients with moderate to severe hepatic impairment has not been established.
Patients with Renal Impairment
No dose adjustment is required for patients with mild to moderate renal impairment.
Data on the use of Glasdegib in patients with severe renal impairment are limited.
Pregnant and Lactating Women
Glasdegib may cause embryo-fetal toxicity and is contraindicated in pregnant women.
Before initiating treatment, it is necessary to confirm that women of childbearing potential are not pregnant. Effective contraceptive measures should be taken during treatment and for 30 days after the last dose.
Lactating women should not breastfeed during treatment and for 30 days after the last dose of Glasdegib.
Pediatric Patients
The effectiveness of Glasdegib in patients under 18 years of age has not been established.
Medication Monitoring for Glasdegib Film-Coated Tablets
Pre-Treatment Assessment
Conduct a detailed inquiry about the history of heart disease and risk factors for QT interval prolongation.
Confirm the pregnancy status of women of childbearing potential.
Evaluate the electrocardiogram (ECG) and electrolyte levels.
Examine the complete blood count, renal function, and hepatic function.
Measure the serum creatine kinase (CK) level.
Understand the situation of concurrent medications, with special attention to drugs that may prolong the QT interval.
Cardiac Monitoring
QT interval prolongation is a significant risk associated with Glasdegib.
Regular ECG monitoring is required during treatment. It is recommended to perform ECG examinations before the start of treatment, one week after the initiation of treatment, and monthly for the subsequent two months.
If QT interval prolongation is detected, measures such as dose adjustment or treatment interruption should be taken according to the severity.
Hematological Monitoring
Regular monitoring of the complete blood count is necessary. It should be done at least once a week during the first month of treatment, and the monitoring frequency should be adjusted based on clinical needs thereafter.
Dose adjustment or treatment interruption may be required in case of severe hematological toxicity.
